Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.79 |
| ▸ | CTSS | P25774 | 1/20 | 0.68 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381241 | 0.91 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2381231 | 0.91 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2381237 | 0.91 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12253433 | 0.91 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3257845 | 0.91 | CTSB (0.74) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12018608 | 0.91 | CTSB (0.74) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3258231 | 0.91 | CTSB (0.74) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3046050 | 0.91 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3046058 | 0.91 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12018629 | 0.91 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20120220520-A1 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | JANSSEN SCIENCES IRELAND UC (IE) | 2012-08-30 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | CTSB 168/4885CTSS 89/4885ADRB3 4099/4885 |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | CTSB 168/4885CTSS 89/4885ADRB3 4099/4885 |
| US-20120220520-A1 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | HAVCR2, CYP7A1, CYP3A4 | CTSB 111/4885CTSS 206/4885ADRB3 3728/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | CTSB 126/4885CTSS 69/4885ADRB3 4075/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | CTSB 168/4885CTSS 89/4885ADRB3 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.